Trial-anchored psychedelic practice guidance

Preview competencies (3)

• Safety monitoring

  Responsibility to monitor the safety of LSD administration in a therapeutic setting. The page explicitly frames the study as evaluating safety and notes prior evidence that LSD can be administered safely in such settings.

• Clinical research protocol adherence

  Ability to operate strictly within a clinical trial protocol and modern research standards. The source emphasizes designing and conducting LSD-assisted psychotherapy studies under regulatory expectations.

• LSD-assisted psychotherapy delivery

  Ability to provide psychotherapy in conjunction with LSD administration within a clinical research setting. This includes supporting participants through experimental sessions and integrating the psychotherapy components of the protocol.

Preview competencies (3)

• Assessment of psychiatric and psychological status

  Ability to evaluate patient status using psychological and psychiatric assessment methods relevant to the intervention. The source indicates use of rating scales, MMPI, and personality assessment.

• Understanding of psychophysiologic and conversion disorders

  Knowledge of the clinical populations and target conditions referenced in the study. A facilitator should understand these disorders and their psychotherapy relevance.

• Outcome monitoring and follow-up

  Ability to monitor changes over time and assess treatment effects after LSD-assisted psychotherapy. Follow-up studies are indicated in the source terms.

Preview competencies (3)

• Monitoring for psychotic deterioration

  Ability to monitor for emergence of psychosis during or after treatment. The source reports that some patients became psychotic and required electroconvulsive therapy.

• LSD psychotherapy administration

  Ability to administer LSD in a psychotherapy setting using the regimen described in the source. The therapist/facilitator must understand session-based dosing and treatment course structure.

• Acute adverse event response

  Capacity to respond to unexpected adverse psychiatric outcomes during LSD psychotherapy. The report indicates serious reactions occurred, even though none were permanently harmed.

Preview competencies (1)

• Trial registry literacy

  Understand how to interpret and use ClinicalTrials.gov study records and glossary information. This supports accurate extraction of study-related requirements and context.

Preview competencies (0)

Competency extraction pending.

Preview competencies (3)

• Deliver LSD-assisted psychotherapy within a medically supervised psychotherapeutic setting

  Therapists/facilitators must be able to provide psychedelic-assisted psychotherapy in a structured clinical environment that integrates psychotherapy with medical supervision. The study explicitly frames safety and efficacy as dependent on administration in a medically supervised, methodologically rigorous setting.

• Monitor acute and short-term adverse effects

  The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.

• Conduct preparatory and integrative psychotherapy

  Treatment included drug-free psychotherapy sessions in addition to LSD-assisted sessions, implying facilitator competence in preparing patients before dosing and supporting processing around the experience. This includes sequencing psychotherapy across multiple visits and linking psychedelic sessions to broader therapeutic goals.

Preview competencies (3)

• Informed consent, decisional capacity, autonomy, and withdrawal rights

  Therapists/facilitators must ensure participants are cognitively able to understand the study and provide their own written informed consent. Consent must be obtained before any study-specific procedures and documented appropriately.

• Suicide risk monitoring

  Therapists/facilitators must monitor for suicidality throughout the study using validated tools and clinical observation. They must escalate concerns promptly and document findings accurately.

• Informed consent, decisional capacity, autonomy, and withdrawal rights

  Facilitators must uphold ethical research principles, including participant autonomy, voluntariness, and the right to withdraw without penalty. They also must avoid coercive or noncompliant practices.

Preview competencies (1)

• Source text unavailable

  The provided source text does not include the guideline content needed to extract therapist/facilitator competencies. Only a download placeholder and site footer text are present.

Preview competencies (3)

• Acute psychological response and emergency management during dosing

  The facilitator should monitor for both positive and negative acute psychological reactions during the session. The source notes that LSD can produce blissful, mystical, and empathogenic effects but can also produce transient negative drug effects, fear, anxiety, and psychosis-like phenomena.

• Therapeutic boundaries, professional conduct, and consent for touch

  Therapists/facilitators must work within legal authorization and avoid contributing to unsafe or unregulated use. The article emphasizes that clinical use occurs only under specific approvals and that professional responsibility includes steering patients away from unproven sources.

• General psychedelic-assisted practice skills

  The facilitator must conduct sessions in a controlled medical or research environment and maintain conditions that support safe administration and monitoring of LSD. This includes ensuring the setting is structured, supervised, and consistent with safety guidelines.

Preview competencies (3)

• Facilitate access to emotions and catharsis

  A central therapeutic skill is helping patients safely enter, tolerate, and process intensified emotions that emerge during LSD sessions. The study highlights facilitated access to emotions, catharsis, crying, grief work, and relief after expression.

• Understand acute psychological effects of LSD

  Facilitators need detailed knowledge of LSD’s acute phenomenology to anticipate and normalize patient experiences. The article describes intensification of affect, altered associations, imagery, weakened ego boundaries, and 6–9 hour duration.

• Monitor and respond to adverse reactions

  A core competency is active safety monitoring for acute, subacute, and lasting adverse effects. Although no lasting negative effects were reported, the study notes temporary intense emotions, initial distress, tiredness, and mild short-term destabilization after sessions.

Preview competencies (3)

• Informed consent delivery

  The investigator is responsible for obtaining valid informed consent before any study procedures. Consent discussions must be understandable, voluntary, documented, and updated when new information emerges.

• Management of acute psychological distress

  Therapists must monitor for panic, paranoia, lack of insight, severe anxiety, insomnia, psychosis, and suicidal thinking, using supportive care first and rescue medication when needed. Continuous observation and extended presence are central safety functions.

• Adverse event detection and documentation

  Therapists/investigators must systematically identify, classify, document, and follow adverse events and serious adverse events. Safety monitoring includes both expected side effects and broader medical or psychiatric complications.

Preview competencies (3)

• Conduct clinician-rated depression assessment

  Treating therapists were responsible for clinician-rated outcome assessment using the Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C). This implies competency in structured depressive symptom evaluation and rating-scale administration.

• Monitor adverse events and tolerability

  Because the trial compared adverse events between dosing groups and evaluated safety, therapists/facilitators need competency in observing, documenting, and responding to adverse events during LSD-assisted therapy. Safety monitoring is a core responsibility in this treatment context.

• Provide supportive psychotherapy alongside LSD dosing

  Therapists/facilitators must be able to deliver supportive psychotherapy as the psychotherapeutic component of LSD-assisted treatment across dosing sessions. The study explicitly used supportive psychotherapy together with drug administration.

Preview competencies (3)

• Voluntary participation and non-coercion

  The handbook explicitly states that the experience should be fully explained and that the subject should accept it voluntarily. Coercion is framed as both unethical and therapeutically counterproductive.

• First-hand experiential training

  The handbook explicitly states that therapists should understand the drug effects through personal experience, because direct familiarity improves empathy, guidance, and integration work. Staff who will interact with patients are ideally similarly trained.

• Use of trust as a therapeutic variable

  Absolute or near-absolute trust is treated as central to stabilizing the experience at a psychedelic rather than paranoid level. Therapists are expected to cultivate, protect, and restore trust throughout the session.

Preview competencies (3)

• Screening, eligibility, and readiness assessment

  Screen for psychiatric risk, medical contraindications, and participant readiness before LSD-assisted sessions.

• General psychedelic-assisted practice skills

  Ensure consent is explicit, ongoing, and matched to the intensity and uncertainty of psychedelic response.

• General psychedelic-assisted practice skills

  Prepare the physical and interpersonal environment to reduce avoidable distress and support therapeutic work.

Preview competencies (3)

• Escalate care when psychological risk becomes acute

  Therapists must know when supportive measures are insufficient and when emergency interventions are required to prevent harm. The guideline indicates escalation to sedative medication or hospitalization when risk to self or others or persistent loss of reality emerges.

• Communicate risks, benefits, and alternatives

  The investigator/therapist has ethical responsibility to explain study goals, course, expected effects, possible advantages and disadvantages, risks, and alternative treatments in verbal and written form. This includes ensuring participant questions are answered satisfactorily and that there is enough time for decision-making.

• Facilitate experiential processing and integration

  Therapists must help participants make sense of material emerging during and after LSD sessions and continue integration over follow-up psychotherapy visits. This includes immediate post-session discussion and additional sessions over the following weeks.